Clinical Trials Logo
  1. Home
  2. Frontal Fibrosing Alopecia
  3. NCT03346668

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

Frontal Fibrosing Alopecia Clinical Trial

Official title:
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

Clinical Trial Summary

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

Clinical Trial Description

Primary scarring alopecias (PSAs) are poorly understood dermatologic disorders that result in permanent hair loss. Most of the scarring alopecias involve a painful course, with individuals reporting scalp pain, burning, itching, or tingling/crawling sensations that can ultimately impact physical and psychological health. There has been no study of topical neurogenic agents, such as gabapentin, to treat scarring alopecia. However topical gabapentin has been safely used in other conditions associated with chronic pain, burning, irritation, itch, or tingling, such as vulvodynia. This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia. In this study, 10 subjects with symptomatic lymphocytic-type scarring alopecia will be recruited and treated with topical gabapentin. Disease burden will be evaluated before and after 12 weeks of treatment through reporting of subjective symptomatology via surveys/questionnaire, neurometer study, clinical assessment, and biopsies measuring levels of CGRP before and after treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03346668
Study type Interventional
Source University of Minnesota
Contact
Status Completed
Phase Early Phase 1
Start date January 28, 2016
Completion date October 11, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04409041 - Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Enrolling by invitation NCT06202560 - Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study N/A
Not yet recruiting NCT03335228 - Platelet Rich Plasma for Frontal Fibrosing Alopecia N/A
Not yet recruiting NCT06240351 - A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) Phase 4
Not yet recruiting NCT02467101 - Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia N/A
Recruiting NCT03422640 - Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Phase 4
Active, not recruiting NCT03082560 - Design and Validation of a New Assessment Tool for Lichen Planopilaris
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT05332366 - A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia Phase 2